Becton, Dickinson Boosts FY23 Outlook - Update

RTTNews | 770 days ago
Becton, Dickinson Boosts FY23 Outlook - Update

(RTTNews) - While reporting financial results for the first quarter on Thursday, medical technology company Becton, Dickinson and Co. or BD (BDX) raised its adjusted earnings and revenue outlook for fiscal 2023.

For fiscal 2023, the company now projects adjusted earnings in a range of $ $12.07 to $12.32 per share on revenues between approximately $19.1 billion to $19.3 billion, with currency-neutral revenue growth of 5.75 to 6.75 percent.

Previously, the company expected adjusted earnings in a range of $11.85 to $12.10 per share on revenues between $18.6 billion to $18.8 billion, with currency-neutral revenue growth of 5.25 to 6.25 percent.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $11.95 per share on revenue decline of 0.30 percent to $18.82 billion for the year. Analysts' estimates typically exclude special items.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

read more
BD Recalls ChloraPrep Clear 1 ML Applicators

BD Recalls ChloraPrep Clear 1 ML Applicators

Medical technology company Becton, Dickinson and Co. or BD has recalled one lot of ChloraPrep Clear 1 mL Applicators citing potential fungal contamination, the U.S. Food and Drug Administration said. Under certain environmental conditions, the contamination allows the growth of Aspergillus penicillioides within the packaging.
RTTNews | 22 days ago
Becton, Dickinson Boosts FY24 Ad, EPS Outlook - Update

Becton, Dickinson Boosts FY24 Ad, EPS Outlook - Update

While reporting financial results for the third quarter on Thursday, medical technology company Becton, Dickinson and Co. (BDX) raised its adjusted earnings guidance for fiscal 2024, while trimming annual revenue outlook.
RTTNews | 224 days ago
BD Announces Global Commercial Release Of New BD FACSDiscover S8 Cell Sorters

BD Announces Global Commercial Release Of New BD FACSDiscover S8 Cell Sorters

Medical technology company BD or Becton, Dickinson and Co. (BDX) announced Friday the global commercial release of new cell sorters that will enable more researchers in a broader range of fields, including cell biology, cancer research and immunology, to reveal insights that were previously invisible in traditional flow cytometry experiments.
RTTNews | 342 days ago
BD Gets FDA 510(k) Clearance For Fingertip Blood Collection Device

BD Gets FDA 510(k) Clearance For Fingertip Blood Collection Device

Medical technology company Becton, Dickinson and Co. or BD (BDX) announced Thursday it has received 510(k) clearances from the U.S. Federal Drug Administration (FDA) for a novel blood collection device that obtains blood samples from a fingerstick that produce lab-quality results for some of the most commonly ordered blood tests.
RTTNews | 462 days ago
Becton, Dickinson Boosts FY23 Outlook - Update

Becton, Dickinson Boosts FY23 Outlook - Update

While reporting financial results for the second quarter on Thursday, medical technology company Becton, Dickinson and Co. (BDX) raised its adjusted earnings and revenue outlook for fiscal 2023.
RTTNews | 679 days ago
Nikkei May Take Further Damage On Friday

Nikkei May Take Further Damage On Friday

The Japanese stock market has alternated between positive and negative finishes through the last five trading days since the end of the two-day winning streak in which it had rallied more than 370 points or 1 percent. The Nikkei 225 now rests just above the 36,790-point plateau and it may extend its losses on Friday.
RTTNews | 4h 17min ago